Therapy-relevant gene signatures in the high risk localized renal cell carcinoma setting: Transcriptomic data from patients receiving placebo on a randomized phase III trial (PROTECT).

Phillip M. Rappold,Andrew W. Silagy,Fengshen Kuo,Mahtab Marker,Albert Reising,John M. Millholland,Paul Russo,Jonathan A. Coleman,Martin H. Voss,Timothy A. Chan,Robert J. Motzer,A. Ari Hakimi

Therapy-relevant gene signatures in the high risk localized renal cell carcinoma setting: Transcriptomic data from patients receiving placebo on a randomized phase III trial (PROTECT).

2021

Phillip M. Rappold
Andrew W. Silagy
Fengshen Kuo
Mahtab Marker
Albert Reising
John M. Millholland
Paul Russo
Jonathan A. Coleman
Martin H. Voss
Timothy A. Chan
Robert J. Motzer
A. Ari Hakimi

353Background: Transcriptomic profiling of the renal cell carcinoma (RCC) tumor microenvironment (TME) has revealed gene signatures predictive of response to therapies in the metastatic setting. Hi...

Keywords:

Oncology
Tumor microenvironment
Placebo
Gene
Internal medicine
Medicine
Renal cell carcinoma
Transcriptome

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations